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A B S T R A C T
Poly(glycerol adipate) (PGA) is a biodegradable, biocompatible, polymer with a great deal of potential in the
ﬁeld of drug delivery. Active drug molecules can be conjugated to the polymer backbone or encapsulated in self-
assembled nanoparticles for targeted and systemic delivery. Here, a range of techniques have been used to
characterise the enzymatic degradation of PGA extensively for the ﬁrst time and to provide an indication of the
way the polymer will behave and release drug payloads in vivo. Dynamic Light Scattering was used to monitor
change in nanoparticle size, indicative of degradation. The release of a ﬂuorescent dye, coupled to PGA, upon
incubation with enzymes was measured over a 96 h period as a model of drug release from polymer drug
conjugates. The changes to the chemical structure and molecular weight of PGA following enzyme exposure
were characterised using FTIR, NMR and GPC. These techniques provided evidence of the biodegradability of
PGA, its susceptibility to degradation by a range of enzymes commonly found in the human body and the
polymer’s potential as a drug delivery platform.
1. Introduction
Poly(glycerol adipate) (PGA) is synthesised by enzymatic poly-
merisation from glycerol and either divinyl adipate, dimethyl adipate or
adipic acid, using Novozym 435 lipase as the catalyst, allowing a high
degree of control over the ﬁnal product [1–4]. Enzymatic polymerisa-
tion is an emerging area of research which provides several beneﬁts as a
method for producing materials for drug delivery compared with more
traditional synthesis methods. The avoidance of metal catalysts re-
moves the risk of toxic metals in the ﬁnal product, while the use of an
enzyme catalyst enables high levels of enantio-, chemo- and regios-
electivity using mild reaction conditions [1]. PGA self-assembles to
form nanoparticles [5] which, with varying levels of stearic acid
modiﬁcation, have been shown to have low cytotoxicity in HL-60 and
HepG2 cells [6,7]. Unmodiﬁed PGA and PGA with a range of amino acid
modiﬁcations have also been shown to have negligible lytic activity in a
haemolytic assay [8]. The presence of the pendant eOH group in the
polymer backbone allows for the conjugation of molecules with a
variety of functional groups through simple coupling reactions, inﬂu-
encing the physicochemical properties of PGA and its ability to en-
capsulate a variety of drugs [6,8–10]. These changes to the polymer as a
result of the modiﬁcations suggest the enzymatic degradation will be
aﬀected due to the enhanced stability, altered hydrophobicity and in-
creased steric hindrance, leading to a potential for tunable breakdown
and release in vivo. Previously, this has been demonstrated through
functionalisation of PGA with N-acyl amino acids via Steglich Ester-
iﬁcation [8]. Additionally, the drug molecules indomethacin [11],
methotrexate [12] and ibuprofen [13] have been successfully coupled
to the polymer backbone. The low toxicity of PGA coupled with the ease
with which it can be synthesised, functionalised with drug molecules
and formulated into nanoparticles means it shows great potential as a
polymeric platform for both targeted and systemic drug delivery.
It is important to understand the degradation properties of polymers
for a number of reasons. From a safety point of view, an awareness of
likely breakdown products facilitates the prediction of potential in vivo
toxicity. Taking PGA as an example, the breakdown products would be
expected to be the starting materials, glycerol and adipic acid, as the
ester bond represents a fairly weak and susceptible point of cleavage
[1,6,14–17]; however without investigation into these breakdown
products it is not possible to guarantee the biocompatibility of this
polymer. Furthermore, knowledge of the cleavage of the pendant side
chains, and the resultant breakdown products, will enable prediction of
the likely in vivo safety proﬁle, prior to cytotoxicity testing of the
breakdown products themselves. Secondly, polymers can be formulated
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into nano- and microparticles; the breakdown of these particles will
aﬀect the mechanisms by which they are cleared from the body [18]
and the release of drug payloads. In terms of eﬃcacy, any drug coupled
to or encapsulated within a polymer tends to require release in order to
achieve therapeutic eﬃcacy [14,15,19]. Consequently, understanding
the way in which this release takes place will inform the design of
dosage regimens and subsequent pharmacokinetic experiments. Ad-
ditionally, susceptibility or indeed a resistance to particular enzymes
may impact on the suitability of a speciﬁc polymer for diﬀerent routes
of administration and disease targets [15]. Understanding the enzy-
matic breakdown of PGA and consequently the way it will behave in
vivo will help to inform any future dosage form design and provide an
indication of the safety and eﬃcacy of formulations prior to costly in
vitro and in vivo experiments.
Previously, the release of methotrexate from a PGA-drug conjugate
has been studied in the presence of porcine carboxylesterase. The en-
zyme was seen to increase the release of methotrexate compared with
buﬀer alone over a period of seven days [12]. This work suggested the
polymer was susceptible to enzymatic degradation but did not focus on
the nature of this degradation in detail or examine the degradation
products. Additionally, the degradation of poly(glycerol sebacate)
(PGS), a polymer with structural similarity to PGA, has been studied by
several groups. However, it is worth noting that PGS is a cross-linked
polymer, whereas the PGA in the present study is not cross-linked and
largely linear [20–22]. PGS is an elastomer which may be of utility as a
tissue scaﬀold and consequently degradation experiments have tended
to focus on bulk characteristics such as the change in ﬁlm weight and
thickness over a period of hours or days. In the case of tissue scaﬀolds,
degradation if too rapid, tends to be seen as a disadvantage. However,
as previously mentioned, for drug delivery breakdown of the polymer at
the target site is greatly advantageous.
The enzymatic degradation, in the presence of six enzymes, of PGA
and a selection of amino acid modiﬁed polymers has been studied in
detail here for the ﬁrst time alongside two new modiﬁcations of PGA;
PGA-Carboxyﬂuorescein, at two levels of substitution, and PGA-poly
(ethylene glycol) (PGA-PEG). Pancreatin, pepsin, lipase and trypsin
were selected as examples of gastrointestinal enzymes in order to give
an indication of the general degradation behaviour of the polymer and
to assess the potential future suitability of PGA for encapsulation or
coating of oral dosage forms. Esterase was selected as it can be detected
in many areas of the body whereas elastase is associated with acute and
chronic inﬂammation in many diseases [23]. A range of techniques has
been employed to allow a comprehensive evaluation of the enzymatic
degradation behaviour of PGA and relative susceptibility to diﬀerent
enzymes. Dynamic Light Scattering (DLS) was used as a rapid screening
method to provide information about particle breakdown and to facil-
itate the selection of enzyme concentrations and conditions. A ﬂuor-
escent dye, carboxyﬂuorescein, coupled to the polymer, was used as a
model of polymer drug conjugates, and as a model for other pendant
groups esteriﬁed to the free hydroxyl group, in order to study release
over time. Finally, Nuclear Magnetic Resonance (NMR), Fourier-
Transform Infra-Red (FTIR) and Gel Permeation Chromatography
(GPC) were combined to characterise the breakdown of the polymer
and identify the breakdown products.
2. Materials & methods
2.1. Materials
Tetrahydrofuran (THF, HPLC grade), petroleum ether (reagent
grade), acetone (HPLC grade), dimethylformamide (DMF, HPLC grade),
sodium hydroxide (NaOH, 2M), HEPES and boric acid were purchased
from Fisher Scientiﬁc (Loughborough, UK). Sodium Benzoate (0.1%)
was purchased from Alfa Aesar (Heysham, UK). Divinyl adipate was
purchased from Tokyo Chemical Industry (Oxford, UK). Acetone‑d6 was
purchased from Acros Organics (Geel, Belgium). Novozym 435
(immobilised on acrylic resin), glycerol, 5(6)-carboxyﬂuorescein (CF),
poly(ethylene glycol) (PEG) methyl ether, 4-dimethylaminopyrridine
(DMAP), N,N'-dicyclohexylcarbodiimide (DCC), phosphate buﬀered
saline (PBS) tablets, Trizma base, potassium phosphate monobasic,
hydrochloric acid (HCl, 5M), sodium chloride, N-succinyl-L-Ala-Ala-
Ala-p-nitroanilide, ethyl butyrate, 4-methylumbellifyl butyrate, 4-me-
thyl umbelliferone, Nα-benzoyl-L-arginine ethyl ester, deuterium oxide
and sodium phosphate monobasic were purchased from Sigma-Aldrich
(Poole, UK). Elastase from porcine pancreas Type I (≥4.0 units/mg
protein), esterase from porcine liver (≥15 units/mg solid), lipase from
porcine pancreas (Type II, 100–500 units/mg protein (using olive oil
(30min incubation)), 30–90 units/mg protein (using triacetin)), pan-
creatin from porcine pancreas (8x USP), pepsin from porcine gastric
mucosa (≥250 units/mg solid) and trypsin from porcine pancreas
(lyophilized powder, 1000–2000 BAEE units/mg solid) were also pur-
chased from Sigma-Aldrich (Poole, UK).
2.2. PGA synthesis
PGA was synthesised following the protocol detailed by Taresco
et al. [1]. Brieﬂy, glycerol (125mmol) and divinyl adipate (125mmol)
were placed in a three-necked round bottom ﬂask with anhydrous tet-
rahydrofuran (THF, 50ml). Novozym 435 (1.1 g) was added and the
resultant mixture stirred at 250 rpm with an overhead stirrer for 24 h at
50 °C. After this time the immobilised enzyme was removed by ﬁltra-
tion and the THF by rotary evaporation. The residue was heated at
90–95 °C for 1 h to deactivate any residual enzyme.
2.3. PGA modiﬁcations
PGA-Carboxyﬂuorescein at two target substitution levels (1% mol/
mol & 5% mol/mol, PGA-CF and PGA-CF5, respectively) and PGA-PEG
(2% mol/mol substitution) were synthesised using a Steglich
Esteriﬁcation, as previously detailed by Taresco et al. [8] This proce-
dure was also used to synthesise PGA-Phe10, PGA-Phe50, PGA-Trp10
and PGA-Trp50; these modiﬁcations aﬀect the physicochemical prop-
erties of the polymer. Phe refers to phenylalanine, Trp to tryptophan
and the number reﬂects the molar percentage of substitution. The
complete reaction scheme for both the production and modiﬁcation of
PGA is shown in Fig. 1. 1H NMR was used to characterise PGA-CF, PGA-
CF5 and PGA-PEG and conﬁrm the couplings were successful; this can
be found in Appendix A1-A3 respectively, whereas the characterisation
of the amino acid modiﬁed polymers has previously been discussed by
Taresco et al. [8].
2.4. Nanoparticle preparation
Nanoparticles were prepared by nanoprecipitation to a ﬁnal con-
centration of 1mg/ml. Polymers were dissolved in acetone (1ml) and
added dropwise to ultrapure water under magnetic stirring. The solvent
was then allowed to evaporate fully. All nanoparticles had a hydro-
dynamic diameter between 50 and 150 nm, measured by DLS (Zetasizer
Nano ZS, Malvern Instruments, Malvern, Worcester).
2.5. Dynamic light scattering
Enzyme solutions (50 μl) were added to nanoparticle suspensions
(250 μl) and the change in size over time at 25 °C was measured by DLS.
The hydrodynamic diameter of the particles, henceforth referred to as
the particle size, was measured at a scattering angle of 173°. Buﬀer
controls, with no enzyme, were also studied to diﬀerentiate the eﬀect of
the enzyme from that of the buﬀer. The concentration of the enzyme
solution was chosen based on examples from literature, where possible.
Where this information was not available several concentrations were
trialled to ﬁnd the optimum level. The assay was stopped when the
polydispersity exceeded 0.8, insuﬃcient sample remained for accurate
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measurement or after 6 h.
The degradation of PGA, PGA-CF and PGA-CF5 was monitored in
the presence of elastase and esterase. Analysis of degradation by elas-
tase was carried out in both Tris buﬀer (0.1 mM, pH 8.0) and Hepes
buﬀer (0.5 M, pH 6.5). The enzyme solution was at a concentration of
1.74 units/ml, assessed using the method provided by Sigma-Aldrich,
[Appendix B.1 Elastase] whereby one unit of elastase is deﬁned as the
amount that will hydrolyse 1.0 µmole of N-succinyl-L-Ala-Ala-Ala-p-
nitroanilide per minute at pH 8.0 at 25 °C in Tris buﬀer (0.1 mM) [24].
For the experiments with esterase 75.3 units/ml of enzyme in borate
buﬀer (10mM, pH 8.0) and 225.9 units/ml in phosphate buﬀered saline
(PBS, pH 7.4) were used as the enzyme solutions. Activity was assessed
using a method available from Sigma-Aldrich, [Appendix B.2 Esterase]
with one unit deﬁned as the amount that will hydrolyse 1.0 μmole of
ethyl butyrate to butyric acid and ethanol per minute at pH 8.0 at 25 °C
in borate buﬀer (10mM) [25].
The degradation of PGA, PGA-PEG, PGA-Phe10 & 50 and PGA-
Trp10 & 50 in the presence of lipase, pancreatin, pepsin and trypsin was
studied. Lipase was prepared in PBS (pH 7.4) to a concentration of
10mg/ml (215.4 units/ml). The novel method used for determining
lipase activity can be found in Appendix B.3 Lipase; one unit was de-
ﬁned as the amount required to cleave 1.0 nmole of 4-methylumbellifyl
butyrate (4-MUB) per minute in Tris buﬀer (pH 7.5, 0.2M) at room
temperature and with a total reaction volume of 3ml. The amount of 4-
MUB cleaved was calculated using a calibration curve of the ﬂuores-
cence intensity of the product, 4-methylumbelliferone [Appendix B.3
Lipase, Fig. B.4]. Pancreatin was prepared in Simulated Intestinal Fluid
(pH 7.5) according to United States Pharmacopeia (USP) speciﬁcations.
Pepsin was prepared in Simulated Gastric Fluid (pH 1.2) according to
USP speciﬁcations. For the experiments with trypsin, 15,582 units/ml
of enzyme in sodium phosphate buﬀer (1 mM, pH 7.6) was used as the
enzyme solution. Trypsin activity was determined using a method
available from Sigma-Aldrich, [Appendix B.4 Trypsin] and one unit was
deﬁned as the amount required to produce a change in absorbance at
253 nm of 0.001 per minute with Nα-Benzoyl-L-arginine ethyl ester as
the substrate with sodium phosphate monobasic buﬀer (67mM, pH 7.6)
at 25 °C in a reaction volume of 3.20ml [26].
2.6. Release of carboxyﬂuorescein by dialysis
Regenerated Cellulose Dialysis Tubing with a 3.5 kDa MWCO (Type
T1, Fisherbrand, Loughborough, UK) was washed in sterile water and
stored in 0.1% sodium benzoate at 4 °C until use. The preparation and
ﬁlling of the dialysis membranes took place in a Class II cabinet to
minimise microbial contamination. Nanoparticles and buﬀer solutions
were passed through a 0.22 μm ﬁlter before use.
PGA-CF5 nanoparticles (2ml, 1 mg/ml) were placed in dialysis
membranes along with enzyme solution and/or buﬀer up to a ﬁnal
volume of 5ml. This was placed in buﬀer (195ml) and incubated at
37 °C in a shaking water bath. Samples were periodically removed and
replaced with fresh buﬀer. Further aliquots of enzyme were added at 3,
6, 24, 48 and 72 h to maintain enzyme activity. Blank experiments were
carried out with each buﬀer with no enzyme present to diﬀerentiate
between hydrolytic and enzymatic degradation. Fluorescence Intensity
was measured in triplicate at an excitation wavelength of 492 nm and
an emission wavelength of 517 nm using a Cary Eclipse Fluorescence
Spectrophotometer (Agilent Technologies, Santa Clara, CA). Calibration
curves of carboxyﬂuorescein in each buﬀer were produced and used to
calculate the concentration in each sample. This concentration was
used to calculate the cumulative percentage molar release of carboxy-
ﬂuorescein over time.
The eﬀect of three enzymes, lipase, esterase and elastase, was stu-
died. The amount of enzyme used here, and for each of the remaining
experiments, was equivalent to that which was used in the DLS ex-
periments, scaled up relative to the amount of polymer used. The lipase
experiments were carried out in phosphate buﬀered saline (PBS) at pH
7.4 with 4mg lipase used for each enzyme addition. Borate buﬀer
(10mM, pH 8.0) was used as the buﬀer with esterase, with 33 units of
esterase used for each enzyme addition. For the elastase experiments
0.82 units were used for each enzyme addition, and Hepes buﬀer
(0.1M) was used at pH 6.5.
2.7. Characterisation of degraded polymer
The degradation of PGA-CF5 in the presence of lipase, esterase and
Fig. 1. Synthesis and Modiﬁcation of PGA. The reaction scheme for the synthesis of PGA and subsequent modiﬁcation by Steglich Esteriﬁcation is shown here.
Adapted from Taresco et al. [1,4].
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elastase was characterised by GPC, FTIR and 1H NMR. The same in-
cubation conditions and pattern of enzyme addition as in the release
experiments were used. The ratio of polymer to enzyme was main-
tained, however, the amount of polymer used was increased to facilitate
analysis. Three incubation times, ranging from 24 to 96 h, were used for
GPC analysis and for the sample incubated with lipase analysed by NMR
and FTIR. The esterase and elastase samples for NMR and FTIR analysis
were incubated for 96 h. After incubation samples were freeze-dried
(Sentry 2.0, Virtis SP Scientiﬁc, Gardiner, NY) to remove the buﬀer.
Gel Permeation Chromatography (GPC, PL50, Polymer
Laboratories, Salop, UK) was carried out using dimethylformamide
(DMF)+0.1% LiBr as the mobile phase at a ﬂow rate of 1ml/min. Two
mixed bed D columns were employed, kept at a constant temperature of
50 °C. Poly(methyl methacrylate) standards (Mn range
1,810,000–505 gmol−1) were used to calibrate the size-exclusion
chromatography system. The enzyme was precipitated with acetone
(3ml per sample) prior to analysis. In addition to the enzyme samples,
controls were carried out using untreated PGA-CF5 and polymer which
had been incubated at 37 °C without enzyme present to allow accurate
interpretation of the eﬀect of the enzymes.
FT-IR spectra were recorded with an Attenuated Total Reﬂection
Cary 630 FTIR spectrophotometer (Agilent Technologies, Santa Clara,
CA). 128 interferograms were recorded for each spectrum in the range
4000–650 cm−1.
1H NMR spectra were recorded using acetone‑d6 and deuterium
oxide on a Bruker 400MHz spectrophotometer (Billerica, MA).
Chemical shifts were reported as parts per million (δ) downﬁeld from
an internal standard, tetramethylsilane. Acetone (1ml per sample, un-
less stated) was used to precipitate the enzyme before analysis.
2.8. Statistical analysis
Two-way ANOVA was performed on the results for the release of
carboxyﬂuorescein in order to determine statistical signiﬁcance. The
percentage carboxyﬂuorescein release in the presence of each enzyme
was compared with the relevant buﬀer without enzyme present.
Following this f-tests were used to determine if the variance of the
groups was signiﬁcantly diﬀerent. This information was used to select
the appropriate two tailed unpaired t-test for each enzyme and buﬀer
pair. A t-test was carried out at each time point to ascertain when there
was a signiﬁcant diﬀerence in release with and without enzyme present,
with signiﬁcance set at a p-value of 0.05.
3. Results
3.1. Change in particle size by Dynamic Light Scattering
DLS was used as a rapid screening technique, monitoring the change
in nanoparticle size and polydispersity following the addition of a small
aliquot of enzyme. The purpose of these experiments was to gain an
insight into how the polymeric nanoparticles may behave in vivo and to
select appropriate conditions for future experiments. This experiment
was intended to provide a binary prediction of whether or not a par-
ticular enzyme would degrade a particular polymer, rather than a
quantitative measure of that degradation. It has been suggested that the
increase in particle size represents swelling, followed by the collapse of
the particle, which can be taken as an indication of degradation [27].
3.1.1. Comparison of diﬀerent enzymes
The eﬀect of each of the diﬀerent enzymes on PGA nanoparticles
was studied to facilitate comparison. Additionally, two buﬀers were
used with both esterase and elastase in order to explore the impact of
pH. Together with buﬀers reﬂecting the optimum pH for activity, es-
terase was studied at pH 7.4 to reﬂect the environment of the blood and
elastase was studied at pH 6.5. In the 1920s Warburg et al. [28,29]
discovered that the tumour microenvironment tends to have a slightly
acidic pH, consequently, understanding the eﬀect of lowering the pH
may be beneﬁcial for future applications of this polymer in cancer drug
delivery.
Simulated gastric ﬂuid caused an increase in particle size exceeding
that seen with pepsin. This is likely to be a result of the acidic pH of this
buﬀer, 1.2, at which the nanoparticles do not appear to be stable.
Consequently, the remainder of the results presented here exclude
pepsin. The eﬀect of the buﬀer was found to be negligible for all of the
other conditions studied.
A dramatic change in PGA nanoparticle size was seen with lipase,
pancreatin and elastase in Hepes buﬀer, suggesting degradation was
occurring. A change in nanoparticle size was also seen with elastase in
Tris buﬀer [Fig. 2]. The eﬀect seen with trypsin was limited, with a
small change in size in the region of 100 nm. Additionally, the eﬀect of
esterase on particle size was limited in borate buﬀer (pH 8) and in PBS
(pH 7.4).
3.1.2. Comparison of diﬀerent polymer modiﬁcations
Nanoparticles made using modiﬁed PGA were tested with each of
the enzymes to investigate the eﬀect of these structural changes on the
extent of degradation. These modiﬁcations were the addition of PEG to
the end of the polymer chain and the conjugation of carboxyﬂuorescein,
at 2% & 5%, or the amino acids phenylalanine and tryptophan, at 10%
and 50%, to the pendant hydroxyl group of the polymer backbone. The
modiﬁed polymers were compared with the unmodiﬁed PGA.
Interestingly, diﬀerences were observed between polymer mod-
iﬁcations incubated with the same enzyme. For lipase, pancreatin and
trypsin the change in size of PGA-PEG nanoparticles was an order of
magnitude less than that seen for the unmodiﬁed PGA [Fig. 2]. The
eﬀect of the other modiﬁcations was less consistent. A change in size
was seen for PGA and the carboxyﬂuorescein modiﬁed polymers upon
incubation with elastase, with the extent of this change diﬀering de-
pending on the level of carboxyﬂuorescein modiﬁcation. With esterase
in both buﬀers there was no size change seen at all for the carboxy-
ﬂuorescein modiﬁed polymers, and a limited eﬀect on the size of PGA
nanoparticles, meaning the diﬀerences between polymers may not be
signiﬁcant. For lipase and pancreatin the amino acid modiﬁcations
appeared to reduce the eﬀect of the enzymes, yet for trypsin the op-
posite was true. Furthermore, for all polymers with trypsin it took some
time before any change in size was seen.
Fig. 2. Eﬀect of Backbone Modiﬁcations on PGA Degradation. The colour of
each bar here reﬂects the polymer under investigation. The results for pepsin
have been omitted as it was not possible to diﬀerentiate the eﬀect of the enzyme
from that of the buﬀer.
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3.2. Release of coupled carboxyﬂuorescein
PGA-CF5 was used here as a model of a low loading of drug coupled
to PGA, allowing the release of carboxyﬂuorescein from the polymer to
be monitored over time. This was to provide an indication of the way a
drug would be released if coupled to the polymer backbone.
Lipase was seen to signiﬁcantly increase the release of carboxy-
ﬂuorescein in comparison with the buﬀer alone [Fig. 3A]. Two-way
ANOVA analysis suggested this diﬀerence was highly signiﬁcant with a
p-value of< 0.0001. Furthermore, studying each time point in-
dividually suggested a signiﬁcant diﬀerence between the release of
carboxyﬂuorescein with and without lipase present from 2 h onwards.
After 96 h the release of carboxyﬂuorescein in the presence of lipase
was calculated as 23% whereas in PBS alone it was 7%. Several distinct
phases could be identiﬁed in the release of the carboxyﬂuorescein.
There was an initial burst release over the ﬁrst few hours; this is
thought to be due to the ester bonds of carboxyﬂuorescein present in
the surface layers of the nanoparticles being easily accessible to the
enzyme and so rapidly cleaved, releasing the dye. Following this there
was a more gradual release of the internal carboxyﬂuorescein before
approaching a plateau from 24 h onwards. The release was not calcu-
lated to be 100%, however, no carboxyﬂuorescein could be detected
within the dialysis membrane, suggesting a spectral shift may be oc-
curring which reduces the apparent concentration of carboxy-
ﬂuorescein. The release seen here is typical for many polymeric nano-
particle formulations [30].
The experiments investigating the eﬀect of elastase were carried out
in the presence of Hepes buﬀer at pH 6.5. These conditions were chosen
as pH 6.5 saw a larger particle size increase by DLS than pH 8.0.
Elastase caused a signiﬁcant increase in carboxyﬂuorescein release
when compared with the buﬀer alone from 48 h onwards, with p-va-
lues< 0.05. The release was calculated as 5.6% with the buﬀer alone
and 9.6% in the presence of elastase after 96 h; this increase was less
than that seen with lipase [Fig. 3B].
Since the DLS results for esterase at both pH values failed to show an
eﬀect, borate buﬀer (pH 8.0) was preferred for these experiments as it
represents the optimum conditions for esterase action. The release of
carboxyﬂuorescein was calculated to be 5.8% in the presence of es-
terase after 96 h, compared with 1.8% with the borate buﬀer alone.
Overall, this diﬀerence was not found to be signiﬁcant. Examining each
time point individually, there was a signiﬁcant diﬀerence in the release
at 6 h (p-value=0.005), however, this diﬀerence was not maintained.
Furthermore, a high level of variability between samples was observed
[Fig. 3C]. Any increase in release seen with esterase is, therefore, likely
to be a result of hydrolytic degradation.
3.3. Change in polymer molecular weight following incubation with enzymes
The release of carboxyﬂuorescein detailed in the previous section
strongly suggests the polymer was breaking down in the presence of
enzymes. In order to analyse this in a quantitative manner, GPC was
used to monitor the eﬀect of incubation with enzymes on the molecular
weight of PGA-CF5. The chromatographs and distribution plots gener-
ated for each sample can be found in the Supplementary Information
Fig. 3. A–C: Release of Carboxyﬂuorescein in the Presence of Lipase, Elastase and Esterase. The release of carboxyﬂuorescein in the presence of lipase, elastase and
esterase is shown in A, B & C, respectively and each graph also shows the relevant buﬀer control. The points used here are the average of three experiments whereas
the error bars represent 1 standard deviation. Calculated p-values for each time point, comparing release with and without the enzyme are indicated by asterisks.
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[Appendix C].
Where no enzyme was present there was relatively little change in
the GPC traces compared with the untreated sample, suggesting PGA
was stable at 37 °C for the duration of the time period studied [Fig. 4A].
Upon incubation with lipase, a dramatic decrease in molecular
weight was observed at 24 h, with a similar result seen for the re-
maining time points [Fig. 4]. The peak representing the intact polymer
as seen in the untreated sample was absent, suggesting no polymer
remained. Only small molecular fragments were detected, however
these could not be quantiﬁed as they approached the calibration limit of
the instrument and the solvent peak.
At each studied time point two peaks were detected for those
samples incubated with elastase; the ﬁrst of these peaks represents a
size consistent with untreated polymer whereas the second represents
small breakdown products [Fig. 4]. Interestingly, with increasing in-
cubation time, the size of the peak representing the intact polymer
decreased relative to the peak of the small breakdown products. This
suggests partial degradation occurs with elastase, with the amount of
intact polymer decreasing over time as the degradation progresses.
The change seen following incubation with esterase was less dra-
matic than that observed with lipase and elastase, with a limited change
in molecular weight [Fig. 4A]. However, the range of molecular weights
appeared to narrow and the polydispersity (Ð) decreased relative to the
untreated sample [Fig. 4B]. This change indicates the loss of small
fractions from the end of the larger polymer chains, rather than
breakages from the centre of the chain.
The GPC analysis conﬁrms that PGA-CF5 is entirely broken down in
the presence of lipase, with no intact polymer chains remaining.
Degradation also occurs to a lesser extent in the presence of elastase,
with both degraded and intact chains present in each sample. Finally,
there is a change in the size distribution of PGA-CF5 incubated with
esterase, suggesting minimal degradation is occurring.
3.4. Changes to chemical structure of PGA following enzyme incubation
The changes to the structure of PGA following the addition of en-
zymes was investigated in order to conﬁrm breakdown was occurring
and to understand the spectral changes seen with the released carbox-
yﬂuorescein.
3.4.1. FTIR
FTIR was used to provide a rapid indication of whether degradation
had occurred. Several diﬀerences can be seen between the spectra of
PGA-CF5 alone and those of the polymer incubated with lipase. The OH
stretch between 3500 and 3000 cm−1 shifts to lower wavelengths with
time, indicative of the presence of carboxylic acid groups, increased
hydrogen bonding and the formation of dimers [Fig. 5A, peak I]. The
peak representing the C]O ester bond at 1750 cm−1, visible in the
untreated sample, is not seen from 72 h of incubation with lipase on-
wards. Instead, there is a broad area of peaks between 1700 and
1500 cm−1, representing overlapping vibrations from a range of dif-
ferent C]O carboxyl bonds [Fig. 5A, peak II]. Finally, there are new
peaks visible in the region of the spectra below 1000 cm−1 which are
not seen with the untreated PGA-CF5; these peaks represent changes to
the environment of the aromatic ring structure of carboxyﬂuorescein
[Fig. 5A, peak III]. These changes to the FTIR spectra appear likely to
show the breakdown of the ester bond, and subsequently the polymer,
on incubation with lipase.
PGA-CF5 incubated with elastase, the untreated polymer and the
enzyme alone were analysed by FTIR and the spectra compared; two
Fig. 4. A & B: GPC Traces, Molecular Weight and Polydispersity of PGA-CF5 Following Enzyme Incubation. In A the traces for each sample are presented, grouped by
enzyme. The large peaks seen in the region of 1000 s represent the eluent. There is little diﬀerence between the untreated sample and the blank samples, incubated
without enzyme, suggesting the changes seen upon incubation with enzymes are as a result of enzymatic degradation. In B the number average molecular weight
(Mn) and Polydispersity (Ð) are listed.
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main areas of diﬀerence were identiﬁed. As with the lipase samples, the
peak at 1750 cm−1 [Fig. 5B, peak I], representing the C]O of the ester
bond, reduced in intensity between the untreated and treated samples,
suggesting a proportion of these bonds were broken. Additionally, three
peaks appeared at 990, 1030 & 1160 cm−1 [Fig. 5B, peak II] in the
sample incubated with enzyme, representing a CeO alcohol bond
forming in place of the ester bond.
PGA-CF5 incubated with esterase, untreated PGA-CF5 and esterase
alone were analysed by FTIR and the spectra compared to ascertain the
eﬀect of the enzyme. The enzyme alone produced two clear peaks at
1530 & 1640 cm−1 [Fig. 5C, peak III] which can also be seen for the
incubated sample. The main diﬀerence between the spectra of the
treated and untreated PGA-CF5 is the OH stretching area at
3500–3000 cm−1, the OH stretching area where the typical broad peak
representative of alcohols, seen in the untreated sample, is replaced by
a sharp acidic peak due to the formation of dimers [Fig. 5C, peak I].
Additionally, the peak at 1720 cm−1 [Fig. 5C, peak II], resulting from
the C]O ester bond, disappears following incubation with the enzyme,
providing further suggestion of breakdown.
3.4.2 1H NMR
1H NMR was used to provide a more detailed examination of the
structural changes following incubation with the enzymes. Analysis was
carried out in acetone‑d6 and deuterium oxide. Any remaining polymer
would be visible in the acetone but would not be present in the deu-
terium oxide, whereas the degradation products would be soluble in
both acetone and deuterium oxide. Consequently, this allowed the de-
gradation products to be identiﬁed more easily in deuterium oxide in
the absence of the intact polymer peaks. Allocation of the peaks cor-
responding to PGA has been discussed previously in detail by Taresco
et al. [1].
Following incubation with lipase, it was possible to observe peaks
corresponding to carboxyﬂuorescein (6.5–8.0 ppm), glycerol
(3.5–4.0 ppm), adipic acid (1.3 ppm) and the intact polymer (1.6, 2.3,
4.0 ppm) in acetone‑d6 [Fig. 6A & B]. Furthermore, a mixture of
breakdown products could be observed in the region of 4.75–5.5 ppm,
with peaks corresponding to a dimer of the repetitive unit of PGA and
carboxyﬂuorescein coupled to one PGA monomer unit. This suggests
that the breakdown is not always complete.
When analysed in deuterium oxide the peaks representing adipic
acid (0.5–2.5 ppm) remain visible; there are many peaks suggesting a
range of variations are present [Fig. 6A & C]. It was possible to study
the glycerol present in more detail; as well as free glycerol (3.6, 3.7, 3.9,
5.1 ppm) there is also a conjugate of glycerol and carboxyﬂuorescein
(4.4 ppm). Additionally, the peak labelled j (8.0–8.3 ppm), which re-
presents the proton adjacent to the ester bond of carboxyﬂuorescein,
shifts with increasing incubation time as the environment changes,
conﬁrming the breakdown of this bond.
The NMR spectra of PGA-CF5 incubated with elastase, recorded in
acetone‑d6 and deuterium oxide, do not diﬀer signiﬁcantly from those
seen with lipase. The same breakdown products can be observed, with
the polymer breaking down both partially and fully. As a result of this
similarity the data is not presented here.
As with the lipase and elastase samples, esterase was precipitated
from the incubated sample before 1H NMR analysis in acetone‑d6 and
deuterium oxide. It proved diﬃcult to precipitate the enzyme from the
sample following freeze drying; a large amount of acetone was required
and the enzyme was seen to be yellow in colour, suggesting carboxy-
ﬂuorescein remained within the precipitate. The spectrum obtained
when analysing the incubated sample in acetone‑d6 appeared to be
broadly similar to the spectra obtained for the lipase and elastase
samples, albeit with less clarity [Fig. 6D]. The peaks for the polymer,
adipic acid, glycerol and carboxyﬂuorescein remained visible. Again,
breakdown products could be seen in the region of 5.0–5.5 ppm, how-
ever, there was no peak visible at 4.75 ppm as was seen for lipase
[Fig. 6A, peak q]. This peak represents the proton adjacent to the sec-
ondary alcohol of glycerol found in the dimer [Fig. 6A]. The presence of
a peak at 5.3 ppm suggests the dimer is produced, however, it is likely
Fig. 5. A–C: FTIR Spectra of PGA-CF5 Before and After Incubation with Enzymes. Incubation with lipase is shown in A, elastase in B and esterase in C. The key
diﬀerences in the spectra are highlighted with blue boxes and the peak allocation is discussed in the text. In all cases the spectrum for untreated PGA-CF5 is shown in
black. For lipase (A) PGA-CF5 after 24 h incubation with lipase is in red; 72 h incubation is in green and 96 h incubation is in dark blue. Lipase alone is shown in sky
blue. For elastase and esterase (B & C), PGA-CF5 incubated with the respective enzyme is shown in red and the enzyme alone is shown in green. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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to be in a small amount. Otherwise, the same breakdown products were
as seen with lipase and elastase.
When analysed in deuterium oxide, the spectrum for PGA-CF5 in-
cubated with esterase lacked deﬁnition. Areas of the spectrum relating
to carboxyﬂuorescein, glycerol and adipic acid could be identiﬁed,
however, it was not possible to allocate speciﬁc peaks. Consequently,
this spectrum has not been displayed here. This is likely to be a result of
the diﬃculty precipitating the enzyme, however, this precipitation was
essential to gain any level of spectral clarity.
4. Discussion
DLS showed that the size of PGA nanoparticles increases after the
addition of a range of enzymes, with the extent of this change diﬀering
depending on the enzyme and polymer modiﬁcations. Lipase and
elastase were found to signiﬁcantly increase the release of carboxy-
ﬂuorescein, compared with buﬀer alone. The calculated release re-
mained below 100%, however, the presence of carboxyﬂuorescein-
monomer and carboxyﬂuorescein-glycerol conjugates, identiﬁed by
NMR, in the polymer degradation products may provide an explanation
for the observed spectral shift, and consequent underestimation of re-
lease. NMR, FTIR and GPC were also used to conﬁrm the breakdown of
the polymer in the presence of lipase, elastase and esterase; complete
breakdown was seen with lipase whereas partial breakdown could be
seen with the other two enzymes.
DLS was used here as a rapid screening method. The limitation of
using DLS to explore enzyme degradation in more detail is that it can be
diﬃcult to understand exactly what is changing and why. Certainly, the
fact that after a point it becomes impossible to gain meaningful results
would support this hypothesis. Furthermore, in this study it was noted
that the attenuator number, automatically selected by the Zetasizer ZS
to provide the best measurements, increased over time. For example,
the addition of elastase in Tris buﬀer to PGA nanoparticles caused the
attenuator number to increase from 5 to 8, suggesting the concentration
of nanoparticles in the sample was decreasing. It must also be noted
that Malvern Panalytical suggest a maximum particle size of 10 μm,
sample dependant, for the Zetasizer ZS [31] and the sizes seen here are
approaching that point. Consequently, small nanometre size diﬀerences
in the micrometre size range may be artefacts of the technique.
The results seen here strongly suggest PGA nanoparticles are sus-
ceptible to degradation by a number of enzymes and that modiﬁcations
of the polymer backbone can inﬂuence this degradation. Further in-
vestigations were, however, required to provide a better understanding
of this. As the breakdown of the polymer and the release of any drug
Fig. 6. A–D: NMR Spectra of PGA-CF5 Incubated with Enzymes and Corresponding Labelled Structures: The labelled structures shown in A correspond with each of
the following spectra examining degradation by lipase, elastase and esterase in acetone‑d6 and deuterium oxide. The spectrum in B is PGA-CF5 after incubation for
24 h in lipase, analysed in acetone‑d6. The spectra for 72 & 96 h were very similar, and so are not shown here. In C analysis was carried out in deuterium oxide. The
top spectrum is after 24 h of incubation with lipase, the middle spectrum after 72 h and the bottom spectrum after 96 h. The spectrum in D is PGA-CF5 following
incubation with esterase, analysed in acetone‑d6. The key diﬀerence between this spectrum and those for elastase and lipase is the absence of one peak from the area
labelled ‘Polymer Breakdown Products’.
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was considered to be more relevant from a drug delivery perspective
than changes in particle morphology, analytical techniques were pre-
ferred to imaging techniques.
Generally, aliphatic polyesters with a short chain between ester
groups, such as PGA, are found to undergo hydrolysis in a biologically
relevant time frame [9]. The use of lipase in the synthesis of the
polymer shows it is a viable substrate and so suggests PGA will be de-
gradable by this enzyme. These features are also found in poly(capro-
lactone) (PCL) which can be synthesised by enzymatic ring opening
polymerisation using lipase. This polymer features 5 carbons between
the ester groups, however, PCL is not enzymatically degraded in vivo
[32]. This may be as a result of the thermal properties; PCL is solid at
both room temperature and 37 °C due to its crystalline nature [32], and
consequently access of the enzyme catalytic site to the ester group may
be restricted. Conversely, PGA is a viscous liquid at 37 °C [1], and this
more ﬂuid nature can be expected to allow easier access of the enzyme,
suggesting why enzymatic degradation may be observed with PGA and
not with PCL. These structural features and physical properties, com-
bined with the use of enzymatic synthesis, indicate PGA may be simi-
larly susceptible to degradation by other hydrolases to a greater extent
than traditional polyesters.
The DLS results gathered here suggest modifying the polymer
backbone aﬀects the susceptibility of PGA to enzymatic degradation. In
the presence of lipase, pancreatin and trypsin PGA-PEG nanoparticles
demonstrated a smaller change in size compared with unmodiﬁed PGA.
This suggests PEG provides a protective role by forming a corona on the
surface of the particles, sterically hindering enzyme access [33]. PGA-
PEG could, therefore, be adopted should a slower breakdown and re-
lease proﬁle be desired. With lipase and pancreatin the amino acid
modiﬁcations appeared to reduce the eﬀect of the enzymes. These
modiﬁcations would be expected to increase the stability of the parti-
cles as a result of π-π stacking of the aromatic rings [8]. This was not
seen with trypsin and may be because trypsin is a protease with high
speciﬁcity for arginine and lysine residues [34], rather than the ester
bonds found in PGA.
The active site of porcine pancreatic lipase (PPL) comprises a cat-
alytic triad, with lid domain loops providing steric hindrance. However,
in aqueous environments hydrogen bonds between the lid and co-lipase
tend to stabilise it in an open conﬁrmation, allowing substrate access
[35], and in this case the breakdown of PGA. Furthermore, the natural
substrates of PPL are glycerol esters, which would explain why it works
eﬀectively on PGA resulting in the structural changes observed by NMR
and FTIR and the absence of intact polymer by GPC. Pancreatin is a
mixed enzyme preparation containing lipase, trypsin, amylase, ribo-
nuclease and protease. Consequently, the eﬀect of pancreatin would be
expected to be a summation of the contribution of each of these en-
zymes, meaning the degradation of PGA by pancreatin would be ex-
pected to equal or exceed that seen with lipase alone.
Porcine pancreatic elastase (PPE) is a serine protease with broad
speciﬁcity [36] and crystalline PPE has been reported to have a rela-
tively open active site [37]. While the speciﬁcity of elastase is generally
discussed in terms of peptides, this open site and the noted broad
speciﬁcity may suggest a reason why release was seen with this parti-
cular enzyme preparation. While breakdown is evident by NMR, FTIR
and GPC, the results were less clear than those seen with lipase. This
may be as a result of the reduced speciﬁcity of the enzyme, when
compared with lipase, resulting in partial degradation. This ﬁnding is in
agreement with the lower release of carboxyﬂuorescein and the pre-
sence of intact polymer following GC analysis of PGA-CF5 incubated
with elastase.
The active site of esterase has been reported to be highly con-
strained as a result of the surrounding amino acids. The Jones Cubic
Space model has been used to predict whether or not a molecule will be
a substrate for carboxyesterase [38]. Carboxyﬂuorescein, PGA and
PGA-CF5 are much larger than the active site deﬁned by this model, and
as a result would not be expected to be substrates for esterase. This
suggests a reason why carboxyﬂuorescein release is limited and also
why a high degree of variability was observed. Whilst there is clear
evidence by NMR and FTIR that PGA-CF5 undergoes degradation in the
presence of esterase, it was more diﬃcult to ascertain the structure of
the breakdown products than was the case with PGA-CF5 incubated
with either lipase or elastase. The low level of carboxyﬂuorescein re-
lease, along with the constrained nature of the active site of the en-
zyme, means this diﬃculty was not unexpected. Furthermore, the small
changes in molecular weight seen when PGA-CF5 was incubated with
esterase, suggesting breakdown at the end of the polymer chains, would
concur with the theory regarding the constrained nature of the active
site of esterase [38], as the steric hindrance would be greatly reduced at
the chain ends.
In general terms the breakdown of PGA seen here is of clinical
importance as it suggests breakdown would also be observed in vivo.
This is crucial from a safety point of view and justiﬁes the label ‘bio-
degradable’. Furthermore, this breakdown, coupled with the eﬀective
release of coupled carboxyﬂuorescein suggests PGA would be viable as
a drug delivery platform as active drug molecules could be expected to
be released in a similar controlled manner. The diﬀerences seen with
the various backbone modiﬁcations suggest the potential for tunable
degradation which may be exploited for controlled release.
Furthermore, the variable degradation and release seen with diﬀerent
enzymes could be used for targeting purposes; release can be expected
to be higher in areas with high concentrations of lipase than where
other enzymes prevail. The susceptibility of PGA to gastro-intestinal
enzymes also opens the possibility for using the polymer for oral drug
delivery in the future.
5. Conclusion
Pancreatin, lipase, elastase and trypsin were all found to cause a
change in the size of PGA nanoparticles, indicative of degradation.
Modiﬁcations of the polymer backbone altered the degree of size
change seen; the eﬀect was particularly pronounced for PGA-PEG,
which consistently showed decreased degradation relative to un-
modiﬁed PGA. Lipase, elastase and esterase were shown to increase the
release of coupled carboxyﬂuorescein from the polymer; this increase
was statistically signiﬁcant with lipase and elastase. GPC analysis of the
molecular weight of PGA-CF5 following incubation with lipase, elastase
and esterase, provided evidence of polymer breakdown while illus-
trating the importance of the speciﬁcity of the enzymes on the extent of
the degradation. Lipase was found to cause complete breakdown of
PGA-CF5 by 24 h, whereas elastase caused partial breakdown and the
eﬀect of esterase was limited. The structure of PGA-CF5 incubated with
lipase, elastase and esterase was analysed to understand the way in
which the polymer was breaking down. The breakdown of the ester
bond in the PGA backbone could be seen along with the release of
carboxyﬂuorescein, a carboxyﬂuorescein-monomer conjugate and a
dimer of PGA.
Taken together, these data demonstrate the high enzymatic de-
gradability of PGA based polymers into non-toxic building blocks by a
range of relevant enzymes. Interestingly, a low level of PEGylation or
varying the nature of the free hydroxyl group in the polymer backbone
by conjugation with amino acids has been shown to aﬀect the sus-
ceptibility of the polymer to degradation. This phenomenon may be
exploited to tune the degradation of PGA for speciﬁc pharmaceutical or
biomedical applications in order to achieve controlled release rates and
breakdown proﬁles, thereby optimising dosage regimens and patient
adherence.
Acknowledgements
This work was funded and supported by the Centre for Doctoral
Training in Advanced Therapeutics and Nanomedicines (School of
Pharmacy, University of Nottingham), Pﬁzer Ltd. and the Engineering
S.M.E. Swainson, et al. European Journal of Pharmaceutics and Biopharmaceutics 142 (2019) 377–386
385
and Physical Sciences Research Council (EPSRC), Grant Numbers: EP/
L01646X and EP/N03371X/1.
Appendix A. Supplementary material
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejpb.2019.07.015.
References
[1] V. Taresco, R.G. Creasey, J. Kennon, G. Mantovani, C. Alexander, J.C. Burley,
M.C. Garnett, Variation in structure and properties of poly(glycerol adipate) via
control of chain branching during enzymatic synthesis, Polymer (Guildf) 89 (2016)
41–49, https://doi.org/10.1016/j.polymer.2016.02.036.
[2] T. Naolou, V.M. Weiss, D. Conrad, K. Busse, K. Mäder, J. Kressler, Fatty acid
modiﬁed poly(glycerol adipate) -Polymeric analogues of glycerides, ACS Symp. Ser.
(2013) 39–52, https://doi.org/10.1021/bk-2013-1135.ch004.
[3] C. Korupp, R. Weberskirch, J.J. Müller, A. Liese, L. Hilterhaus, Scaleup of lipase-
catalyzed polyester synthesis, Org. Process Res. Dev. 14 (2010) 1118–1124, https://
doi.org/10.1021/op1000868.
[4] L.E. Iglesias, Y. Fukuyama, H. Nonami, R. Erra-Balsells, A. Baldessari, A simple
enzymatic procedure for the synthesis of a hydroxylated polyester from glycerol and
adipic acid, Biotechnol. Tech. 13 (1999) 923–926, https://doi.org/10.1023/
A:1008958212814.
[5] V.M. Weiss, T. Naolou, G. Hause, J. Kuntsche, J. Kressler, K. Mäder, Poly(glycerol
adipate)-fatty acid esters as versatile nanocarriers: From nanocubes over ellipsoids
to nanospheres, J. Control. Release. 158 (2012) 156–164, https://doi.org/10.1016/
J.JCONREL.2011.09.077.
[6] P. Kallinteri, S. Higgins, G.A. Hutcheon, C.B. St, M.C. Garnett Pourçain, Novel
functionalized biodegradable polymers for nanoparticle drug delivery systems,
Biomacromolecules 6 (2005) 1885–1894, https://doi.org/10.1021/bm049200j.
[7] V.M. Weiss, T. Naolou, T. Groth, J. Kressler, K. Mäder, In vitro toxicity of stearoyl-
poly(glycerol adipate) nanoparticles, J. Appl. Biomater. Funct. Mater. 10 (2012)
163–169, https://doi.org/10.5301/JABFM.2012.10294.
[8] V. Taresco, J. Suksiriworapong, I.D. Styliari, R.H. Argent, S.M.E. Swainson,
J. Booth, E. Turpin, C.A. Laughton, J.C. Burley, C. Alexander, M.C. Garnett, New N-
acyl amino acid-functionalized biodegradable polyesters for pharmaceutical and
biomedical applications, RSC Adv. 6 (2016) 109401–109405, https://doi.org/10.
1039/c6ra21464a.
[9] V. Taresco, J. Suksiriworapong, R. Creasey, J.C. Burley, G. Mantovani,
C. Alexander, K. Treacher, J. Booth, M.C. Garnett, Properties of acyl modiﬁed poly
(glycerol-adipate) comb-like polymers and their self-assembly into nanoparticles, J.
Polym. Sci. Part A Polym. Chem. 54 (2016) 3267–3278, https://doi.org/10.1002/
pola.28215.
[10] S. Puri, P. Kallinteri, S. Higgins, G.A. Hutcheon, M.C. Garnett, Drug incorporation
and release of water soluble drugs from novel functionalised poly(glycerol adipate)
nanoparticles, J. Control. Release 125 (2008) 59–67, https://doi.org/10.1016/j.
jconrel.2007.09.009.
[11] T. Wersig, M.C. Hacker, J. Kressler, K. Mäder, Poly(glycerol adipate) – in-
domethacin drug conjugates – synthesis and in vitro characterization, Int. J. Pharm.
531 (2017) 225–234, https://doi.org/10.1016/J.IJPHARM.2017.08.093.
[12] J. Suksiriworapong, V. Taresco, D.P. Ivanov, I.D. Styliari, K. Sakchaisri,
V.B. Junyaprasert, M.C. Garnett, Synthesis and properties of a biodegradable
polymer-drug conjugate: Methotrexate-poly(glycerol adipate), Colloids Surf. B
Biointerf. 167 (2018) 115–125, https://doi.org/10.1016/j.colsurfb.2018.03.048.
[13] C.J. Thompson, D. Hansford, D.L. Munday, S. Higgins, C. Rostron, G.A. Hutcheon,
Synthesis and evaluation of novel polyester-ibuprofen conjugates for modiﬁed drug
release, Drug Dev. Ind. Pharm. 34 (2008) 877–884, https://doi.org/10.1080/
03639040801929075.
[14] M. Dunne, O.I. Corrigan, Z. Ramtoola, Inﬂuence of particle size and dissolution
conditions on the degradation properties of polylactide-co-glycolide particles,
Biomaterials 21 (2000) 1659–1668, https://doi.org/10.1016/S0142-9612(00)
00040-5.
[15] E. Marin, M.I. Briceño, C. Caballero-George, Critical evaluation of biodegradable
polymers used in nanodrugs, Int. J. Nanomed. 8 (2013) 3071–3091, https://doi.
org/10.2147/IJN.S47186.
[16] J. Park, M. Ye, K. Park, Biodegradable polymers for microencapsulation of drugs,
Molecules 10 (2005) 146–161, https://doi.org/10.3390/10010146.
[17] T. Tarvainen, M. Malin, T. Suutari, M. Pöllänen, J. Tuominen, J. Seppälä,
K. Järvinen, Pancreatin enhanced erosion of and macromolecule release from 2,2-
bis(2-oxazoline)-linked poly(ε-caprolactone), J. Control. Release 86 (2003)
213–222, https://doi.org/10.1016/S0168-3659(02)00372-3.
[18] M. Longmire, P.L. Choyke, H. Kobayashi, Clearance properties of nano-sized par-
ticles and molecules as imaging agents: considerations and caveats, Nanomedicine 3
(2008) 703–717, https://doi.org/10.2217/17435889.3.5.703.
[19] H.S. Azevedo, R.L. Reis, Understanding the enzymatic degradation of biodegradable
polymers and strategies to control their degradation rate, Biodegrad. Syst. Tissue
Eng. Regen. Med. CRC Press, Boca Raton, FL, 2005, pp. 177–201.
[20] Q. Chen, X. Yang, Y. Li, A comparative study on in vitro enzymatic degradation of
poly(glycerol sebacate) and poly(xylitol sebacate), RSC Adv. 2 (2012) 4125–4134,
https://doi.org/10.1039/c2ra20113e.
[21] I. Pomerantseva, N. Krebs, A. Hart, C.M. Neville, A.Y. Huang, C.A. Sundback,
Degradation behavior of poly(glycerol sebacate), J. Biomed. Mater. Res. Part A 4
(2008) 1038–1047, https://doi.org/10.1002/jbm.a.32327.
[22] S. Liang, X. Yang, X. Fang, W.D. Cook, G.A. Thouas, Q. Chen, In Vitro enzymatic
degradation of poly(glycerol sebacate) -based materials, Biomaterials 32 (2011)
8486–8496, https://doi.org/10.1016/j.biomaterials.2011.07.080.
[23] M.M. Muley, A.R. Reid, B. Botz, K. Bölcskei, Z. Helyes, J.J. McDougall, Neutrophil
elastase induces inﬂammation and pain in mouse knee joints via activation of
proteinase-activated receptor-2, Br. J. Pharmacol. 173 (2016) 766–777, https://doi.
org/10.1111/bph.13237.
[24] Sigma-Aldrich, Elastase (EC 3.4.21.36) continuous spectrophotometric rate assay,
n.d. http://www.sigmaaldrich.com/technical-documents/protocols/biology/
enzymatic-assay-of-elastase.html (accessed March 7, 2017).
[25] Sigma-Aldrich, Enzymatic Assay of Esterase, n.d. http://www.sigmaaldrich.com/
technical-documents/protocols/biology/enzymatic-assay-of-esterase.html (ac-
cessed March 7, 2017).
[26] Sigma-Aldrich, Procedure for Enzymatic Assay of Trypsin (EC 3.4.21.4), n.d. http://
www.sigmaaldrich.com/technical-documents/protocols/biology/enzymatic-assay-
of-trypsin.html (accessed March 7, 2017).
[27] C. Colombo, L. Dragoni, S. Gatti, R.M. Pesce, T.R. Rooney, E. Mavroudakis,
D. Moscatelli, Tunable degradation behavior of PEGylated polyester-based nano-
particles obtained through emulsion free radical polymerization, Ind. Eng. Chem.
Res. 53 (2014) 9128–9135, https://doi.org/10.1021/ie4036077.
[28] O. Warburg, The metabolism of carcinoma cells, J. Cancer Res. 9 (1925) 148–163,
https://doi.org/10.1158/jcr.1925.148.
[29] O. Warburg, F. Wind, N. Negelein, The metabolism of tumors in the body, J. Gen.
Physiol. 8 (1927) 519–530, https://doi.org/10.1085/jpg.8.6.519.
[30] N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable controlled-release
polymers and polymeric nanoparticles: mechanisms of controlling drug release,
Chem. Rev. 116 (2016) 2602–2663, https://doi.org/10.1021/acs.chemrev.
5b00346.
[31] Malvern Panalytical, Zetasizer Nano ZS, 2018. https://www.malvernpanalytical.
com/en/products/product-range/zetasizer-range/zetasizer-nano-range/zetasizer-
nano-zs (accessed September 27, 2018).
[32] M. Labet, W. Thielemans, Synthesis of polycaprolactone: a review, Chem. Soc. Rev.
38 (2009) 3484–3504, https://doi.org/10.1039/b820162p.
[33] J.S. Suk, Q. Xu, N. Kim, J. Hanes, L.M. Ensign, PEGylation as a strategy for im-
proving nanoparticle-based drug and gene delivery, Adv. Drug Deliv. Rev. 99
(2016) 28–51, https://doi.org/10.1016/j.addr.2015.09.012.
[34] J.V. Olsen, S.-E. Ong, M. Mann, Trypsin cleaves exclusively C-terminal to arginine
and lysine residues, Mol. Cell. Proteom. 3 (2004) 608–614, https://doi.org/10.
1074/mcp.T400003-MCP200.
[35] A.A. Mendes, P.C. Oliveira, H.F. De Castro, Properties and biotechnological appli-
cations of porcine pancreatic lipase, J. Mol. Catal. B Enzym. 78 (2012) 119–134,
https://doi.org/10.1016/j.molcatb.2012.03.004.
[36] M.M. Burrell, Enzymes in molecular biology, in: J.M. Walker (Ed.), Methods Mol.
Biol. Humana Press, Totawa, New Jersey, 1993, pp. 283–284.
[37] W. Bode, E. Meyer, J.C. Powers, Human leukocyte and porcine pancreatic elastase:
X-ray crystal structures, mechanism, substrate speciﬁcity, and mechanism-based
inhibitors, Biochemistry 28 (1989) 1951–1963, https://doi.org/10.1021/
bi00431a001.
[38] E.J. Toone, M.J. Werth, J.B. Jones, Active-site model for interpreting and predicting
the speciﬁcity of pig liver esterase, J. Am. Chem. Soc. 112 (1990) 4946–4952,
https://doi.org/10.1021/ja00168a047.
S.M.E. Swainson, et al. European Journal of Pharmaceutics and Biopharmaceutics 142 (2019) 377–386
386
